These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8674179)

  • 21. Staphylokinase-specific cell-mediated immunity in humans.
    Warmerdam PA; Vanderlick K; Vandervoort P; De Smedt H; Plaisance S; De Maeyer M; Collen D
    J Immunol; 2002 Jan; 168(1):155-61. PubMed ID: 11751958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Staphylokinase and its mutants: a new generation of thrombolytic agents].
    Lebrazi J; Elalamy I; Helft G; Samama MM
    J Mal Vasc; 1998 Apr; 23(2):92-8. PubMed ID: 9608920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrin-selective thrombolytic therapy with recombinant staphylokinase.
    Collen D; Vanderschueren S; Van de Werf F
    Haemostasis; 1996 Oct; 26 Suppl 4():294-300. PubMed ID: 8979135
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.
    Collen D; De Cock F; Stassen JM
    Circulation; 1993 Mar; 87(3):996-1006. PubMed ID: 8443918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of staphylokinase by enzyme-linked immunosorbent assay using monoclonal antibodies.
    Mike A; Ohya Y; Ohwaki M; Sakai M; Sako T; Watanabe T; Yokokura T
    Biol Pharm Bull; 1994 May; 17(5):564-7. PubMed ID: 7522729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Large-scale preparation of the delta10 form of staphylokinase by in vitro processing of recombinant staphylokinase with purified human plasminogen.
    Chattopadhyay D; Stewart JE; DeLucas LJ
    Appl Biochem Biotechnol; 1998 Mar; 69(3):147-56. PubMed ID: 9554081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and intein-mediated purification of novel staphylokinase SakSTAR with reduced immunogenicity and antiplatelet and antithrombin activation.
    Kochanowski R; Kotlowski R; Szweda P
    Appl Biochem Biotechnol; 2007; 141(2-3):321-33. PubMed ID: 18025559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression, purification and characterization of a novel staphylokinase with anti-platelet aggregation activity].
    Jingfang D; Jintian H; Ruiguang X; Xi C; Baohua Z
    Wei Sheng Wu Xue Bao; 2008 Sep; 48(9):1186-91. PubMed ID: 19062642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel recombinant thrombolytic and antithrombotic staphylokinase variants with an RGD motif at their N-termini.
    He J; Di J; Xu R; Zhao B
    Biotechnol Appl Biochem; 2008 May; 50(Pt 1):17-23. PubMed ID: 18039183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High resolution mapping of the B cell epitopes of staphylokinase in humans using negative selection of a phage-displayed antigen library.
    Jenné S; Brepoels K; Collen D; Jespers L
    J Immunol; 1998 Sep; 161(6):3161-8. PubMed ID: 9743384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of site-specific PEGylation on the fibrinolytic activity, immunogenicity, and pharmacokinetics of staphylokinase.
    Liu J; Wang Z; He J; Wang G; Zhang R; Zhao B
    Acta Biochim Biophys Sin (Shanghai); 2014 Sep; 46(9):782-91. PubMed ID: 25098624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based antigenic epitope and PEGylation improve the efficacy of staphylokinase.
    Xu Y; Shi Y; Zhou J; Yang W; Bai L; Wang S; Jin X; Niu Q; Huang A; Wang D
    Microb Cell Fact; 2017 Nov; 16(1):197. PubMed ID: 29137636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicology studies with recombinant staphylokinase and with SY 161-P5, a polyethylene glycol-derivatized cysteine-substitution mutant.
    Moons L; Vanlinthout I; Roelants I; Moreadith R; Collen D; Rapold HJ
    Toxicol Pathol; 2001; 29(3):285-91. PubMed ID: 11442014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Staphylokinase for a better thrombolytic treatment of heart and platelet diseases].
    Vanderschueren S
    Verh K Acad Geneeskd Belg; 2000; 62(1):69-75. PubMed ID: 10769618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombolytic agents in development.
    Verstraete M; Lijnen HR; Collen D
    Drugs; 1995 Jul; 50(1):29-42. PubMed ID: 7588087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.
    Collen D; Lijnen HR; Vanderschueren S
    Verh K Acad Geneeskd Belg; 1995; 57(3):183-96; discussion 196-8. PubMed ID: 7483814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of action and thrombolytic potential of staphylokinase.
    Lijnen HR
    Verh K Acad Geneeskd Belg; 1995; 57(4):303-14. PubMed ID: 8571666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purification and characterization of a staphylokinase variant, K35R.
    He J; Wang G; Li G; Zhao B; Mo W; Song H
    Biotechnol Appl Biochem; 2006 Jul; 45(Pt 1):43-9. PubMed ID: 16623662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26.
    Schlott B; Hartmann M; Gührs KH; Birch-Hirschfeld E; Gase A; Vettermann S; Collen D; Lijnen HR
    Biochim Biophys Acta; 1994 Feb; 1204(2):235-42. PubMed ID: 8142464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase.
    Vanderschueren S; Stockx L; Wilms G; Lacroix H; Verhaeghe R; Vermylen J; Collen D
    Circulation; 1995 Oct; 92(8):2050-7. PubMed ID: 7554181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.